^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    hydroxychloroquine

    Company:
    Generic mfg.
    Drug class:
    Immunomodulator, PLA2 inhibitor
    Related drugs:
    4d
    TIPS: Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial
    |
    ABCA3 (ATP Binding Cassette Subfamily A Member 3) • SFTPA1 (Surfactant Protein A1)
    |
    prednisone • hydroxychloroquine
    4d
    Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) (clinicaltrials.gov)
    P2, N=50, Completed, Shanghai Children's Hospital | Recruiting --> Completed
    Trial completion
    |
    COL4A5 (Collagen Type IV Alpha 5 Chain)
    |
    hydroxychloroquine
    7d
    Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer. (PubMed, Oncologist)
    The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.
    P1 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • RAS mutation
    |
    Mektovi (binimetinib) • hydroxychloroquine
    17d
    PANoptosis-triggering GA-based biomimetic nano-prodrug remodels the tumor microenvironment to enhance antitumor immunity. (PubMed, Biomaterials)
    CM@pGGH is synthesized by conjugating GA and hydroxychloroquine (HCQ)-an FDA-approved antimalarial and immunomodulator-to polyglutamic acid (PGA) using disulfide and ester linkages, followed by incorporation of a hybrid membrane derived from tumor cell and macrophage...In vivo, CM@pGGH reprograms the tumor immune microenvironment by repolarizing tumor-associated macrophages to a pro-inflammatory M1 phenotype and promoting CD8+ T-cell infiltration, resulting in significant PANoptosis-driven immunogenic cell death (ICD) and sustained antitumor immunity. These findings highlight a dual-prodrug and immune-reprogramming strategy with potential for treating refractory cancers.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    hydroxychloroquine
    21d
    Optical Coherence Tomography Angiography Evaluation Of Patients Taking Hydroxychloroquine (clinicaltrials.gov)
    P=N/A, N=90, Not yet recruiting, Sohag University
    New trial
    |
    hydroxychloroquine
    22d
    Hydroxychloroquine to control gluten-specific T cells in coeliac disease. (ACTRN12626000177358)
    P4, N=30, Not yet recruiting, Walter and Eliza Hall Institute of Medical Research
    New P4 trial
    |
    hydroxychloroquine
    24d
    Life-Threatening Thrombotic Events Revealing Systemic Lupus Erythematosus in a Patient with Chronic Myelomonocytic Leukaemia. (PubMed, Eur J Case Rep Intern Med)
    There is a two-way relationship between hematologic malignancies and autoimmune diseases, where each can potentially initiate or exacerbate the other.Effective management requires close collaboration between haematologists, immunologists/rheumatologists, and intensive care specialists.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Venclexta (venetoclax) • azacitidine • Jakafi (ruxolitinib) • hydroxychloroquine • hydroxyurea
    29d
    ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment. (PubMed, bioRxiv)
    We have previously shown that the combination of GPH (gemcitabine, paricalcitol, and hydroxychloroquine) influences PDAC TME. Targeting integrin αvβ3 using ProAgio modulates the PDAC TME by improving perfusion, reducing hypoxia, reversing EMT, and alleviating immune suppression. ProAgio potentiates the effects of GPH therapy, which should be evaluated in future trials.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    gemcitabine • hydroxychloroquine
    30d
    APLAQUINE: Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome (clinicaltrials.gov)
    P2, N=25, Completed, University Hospital, Rouen | Unknown status --> Completed
    Trial completion
    |
    hydroxychloroquine
    1m
    Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    gemcitabine • docetaxel • hydroxychloroquine
    1m
    A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration (clinicaltrials.gov)
    P1/2, N=57, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Jun 2030 --> Mar 2026 | Trial primary completion date: Mar 2027 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    BRAF V600E • BRAF V600 • BRAF fusion
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine
    1m
    Study on the Efficacy and Safety of Short-Course Telitacicept in Sjögren's Syndrome (ChiCTR2600117190)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University
    New trial
    |
    hydroxychloroquine